Company K Partners
VC Fund
Ilsangu, South Korea
Company K Partners is a VC fund in Ilsangu focused on Biotechnology and Health Care. Company K Partners Limited is a principal investment firm specializing in investments in culture content, electronic components, computer, machinery, broadcasting, arts, sports, and leisure industries. The firm primarily invests in South Korea with a focus in Seoul, Gyeongnam, and Gyeonggi. Company K Partners Limited was established in 2006 and isbased in Gyeonggi-do, South Korea.
- Total investments:
- 188
- Last investment:
- Lead investor:
- 10%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Company K Partners invests in
Stages Company K Partners invests in
Countries Company K Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series A
- $2.2M–$17M
- Series B
- $6.5M–$42M
Investment Focus
Industry
- Biotechnology 38 (20%)
- Health Care 24 (13%)
- Artificial Intelligence 20 (11%)
- Software 17 (9%)
- Therapeutics 15 (8%)
Stage
- Series A 53 (28%)
- Series B 42 (22%)
- Funding Round 18 (10%)
- Venture - Series Unknown 18 (10%)
- Seed 16 (9%)
Country
- South Korea 118 (63%)
- United States 5 (3%)
- Singapore 2 (1%)
- Gibraltar 1 (1%)
- Russian Federation 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hak-beom Kim
Founder & CEO
|
Founder & CEO | Total investments: 0 | Find email | |
Jae Won D
Principal
|
Principal | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
StepLab
|
StepLab is a microsatellite systems company specializing in space mechanism technology, developing innovative satellite platforms and advanced aerospace solutions that support efficient satellite deployment, in-orbit operations, and a wide range of commercial and scientific space missions. | $7.7M / Series A / Aug 05, 2026 | |
Prazer Therapeutics
|
Prazer Therapeutics assists patients suffering from intractable diseases through the use of logical and innovative drug design approaches. They willaccomplished this through the use of new and innovative drug development platforms, such as rational molecular drug design technology and next-generation protein degradation technology. | $33.9M / Venture - Series Unknown / Jul 23, 2026 | |
EtherNafusion
|
EtherNafusion is an early-stage South Korean deep-tech startup developing compact modular nuclear fusion reactors. | $1.5M / Seed / Jul 06, 2026 | |
AccuOptotech
|
AccuOptotech develops advanced semiconductor inspection equipment, including ultra-high-resolution thermal imaging and non-destructive glass core substrate inspection systems | $1.3M / Series A / May 26, 2026 | |
WIRobotics
|
WIRobotics is a Wearable robot that lessen physical demands on your body to safely allow active motion. | $63.5M / Series B / May 15, 2026 | |
Intergravity
|
Intergravity is a company that is developing orbital transportation technologies to support the future of in-space activity. Intergravity is to enable a space environment in which mobility, service, and logistics are seamlessly integrated, creating the framework for long-term operations beyond Earth. | $5.4M / Seed / Apr 13, 2026 | |
Mobilint
|
Mobilint is an AI semiconductor company focused on developing low-power neural processing units (NPUs) and edge AI chips for on-device artificial intelligence applications. Its technology supports AI computing, vision processing, robotics, surveillance systems, and industrial devices. The company aims to improve AI efficiency and reduce energyconsumption across edge computing environments. | $46.4M / Series C / Apr 01, 2026 | |
Bind
|
Bind is a start-up that operates the mobile and PC version of 'Athler'. | $6.7M / Series B / Mar 17, 2026 | |
|
Bind
|
Bind is a start-up that operates the mobile and PC version of 'Athler'. | $6.7M / Series B / Mar 17, 2026 | |
Orum Therapeutics
|
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M / Post-IPO Equity / Dec 18, 2025 | |
| See all 188 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Company K Partners invest in?
Company K Partners invests primarily in Biotechnology, Health Care and Artificial Intelligence startups, most often at Series A and Series B stage. Most of the 188 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Company K Partners's check size?
Company K Partners typically joins rounds of $2.2M–$17M at Series A and $6.5M–$42M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Company K Partners participates in.
How do I contact Company K Partners?
Public channels for Company K Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Company K Partners?
The team at Company K Partners includes Hak-beom Kim (Founder & CEO) and Jae Won D (Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
